Atallah, Ehab
Mauro, Michael J.
Hochhaus, Andreas
Boquimpani, Carla
Minami, Yosuke
Maheshwari, Vikalp Kumar
Saini, Lovneet
Corbin, Regina
Réa, Delphine
Funding for this research was provided by:
Novartis Services Incorporation, East Hanover, NJ, USA
Article History
Received: 8 November 2022
Accepted: 26 December 2022
First Online: 28 January 2023
Declarations
:
: EA reports receiving consulting fees from Novartis, Bristol Myers Squibb, Takeda, and AbbVie. MM reports receiving consulting fees from Bristol Myers Squibb, Takeda, and Pfizer. AH reports receiving consulting fees from Novartis, Bristol Myers Squibb, Pfizer, and Incyte. CB serves on the speakers bureau of Novartis, Jansen, and Pint Pharma; on the board of directors or advisory committees of Novartis and Jansen. YM reports receiving honoraria from Novartis, BMS, Pfizer, and Astellas. LS is an employee of Novartis Healthcare Pvt. Ltd. RC was an employee of Novartis Services Inc. at the time of development of this manuscript. VM was an employee of Novartis Healthcare Pvt. Ltd. at the time of development of this manuscript. DR reports receiving honoraria from Novartis, Incyte, and Pfizer.